	US 11,733,235 B2
	Method for evaluating immunogenicity of test substance
Chiyomi Kubo, Shizuoka (JP); Shigeki Motoyama, Shizuoka (JP); and Yoshiyuki Arata, Shizuoka (JP)
Assigned to Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Appl. No. 16/471,834
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
PCT Filed Dec. 26, 2017, PCT No. PCT/JP2017/046517 § 371(c)(1), (2) Date Jun. 20, 2019, PCT Pub. No. WO2018/124005, PCT Pub. Date Jul. 5, 2018.
Claims priority of application No. 2016-252235 (JP), filed on Dec. 27, 2016.
Prior Publication US 2020/0191770 A1, Jun. 18, 2020
Int. Cl. G01N 33/50 (2006.01); C12Q 1/06 (2006.01); G01N 33/15 (2006.01)

CPC G01N 33/505 (2013.01) [C12Q 1/06 (2013.01); G01N 33/15 (2013.01); G01N 2333/55 (2013.01)]

10 Claims

1. A method for evaluating immunogenicity of a test substance, the method comprising the steps of:

(a) providing a population of peripheral blood mononuclear cells (PBMCs) from which population CD8⁺ T cells or CD25⁺ T cells have been depleted;

(b) culturing the population of cells with a test substance; and

(c) measuring the proportion of IL-2-secreting CD4+ T cells in the cell population cultured in step (b) between 24 hours and 72 hours after initiation of the culturing.